产品说明书
Astragaloside I
 |
同义名 : | Astrasieversianin IV;Cyclosieversioside B;AST-I;AS-I;AstragalosideⅠ |
| CAS号 : | 84680-75-1 | |
| 货号 : | A719044 | |
| 分子式 : | C45H72O16 | |
| 纯度 : | 98% | |
| 分子量 : | 869.044 | |
| MDL号 : | MFCD30478908 | |
| 存储条件： |
粉末 Keep in dark place,Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(57.53 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Astragaloside I (As-I), one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. As-I stimulated the expression of β-catenin and Runx2 in MC3T3-E1 cells. Furthermore, As-I also increased BMP-2, BGP and OPG/RANKL expression, which are also activated by Wnt/β-catenin signaling pathway. Astragaloside I stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway. Astragaloside I (10-40 μM) upregulates the express of β-catenin, Runx2, BGP and OPG, RANKL (osteogenesis marker genes) in MC3T3-E1 cells[2]. Astragaloside I (A), levistilide A (L) and calycosin (C) produced synergistic proliferation inhibition on LX-2 cells and TGF-β1-activated LX-2 cells. Administration of the ALC formula markedly decreased collagen deposition, hydroxyproline (Hyp) content and α-SMA expression levels in the liver tissues compared to the model mice. Astragaloside I, levistilide A and calycosin may be the 3 main bioactive components in DBT(Danggui Buxue Tang); their combination exerts anti-liver fibrosis effects in vitro and in vivo[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.15mL 0.23mL 0.12mL |
5.75mL 1.15mL 0.58mL |
11.51mL 2.30mL 1.15mL |
| 参考文献 |
|---|